JavaScript is disabled for your browser. Some features of this site may not work without it.
    • العربية
    • 中文
    • English
    • français
    • русский
    • español
    • Deutsch
    • português
English
  • العربية
  • 中文
  • English
  • français
  • русский
  • español
  • Deutsch
  • português
  • Home
  • Contact
  • Help

Browse

All of IRISCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

Statistics

Most PopularBy Country

Related Links

PAHO IRISWPRO IRIS

WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis

Thumbnail
View/Open
9789241550079-eng.pdf (‎1.111Mb)‎
Rights
cbna
View Statistics
Show Statistical Information
Altmetrics
Share
Citation
World Health Organization. (‎2018)‎. WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis. World Health Organization. http://www.who.int/iris/handle/10665/260494. License: CC BY-NC-SA 3.0 IGO
Description
xi, 31 p.
Gov't Doc #
WHO/CDS/TB/2018.7
ISBN
9789241550079
Collections
  • Publications
  • Publications
  • Publications
Language
English
Metadata
Show full item record

Related items

Showing items related by title and MeSH subject.

  • Thumbnail

    The use of molecular line probe assay for the detection of resistance to isoniazid and rifampicin: policy update 

    World Health Organization (‎2016)‎
  • Thumbnail

    Comparison of the effectiveness of 2 treatment regimens in patients with isoniazid-resistant tuberculosis 

    Tabarsi, P.; Baghaei, P.; Hemmati, N.; Mirsaeidi, M.; Kazempour, M.; Mansouri, D.; Masjedi, M.R. (‎2009)‎
    We compared the effectiveness of 2 treatment regimens for isoniazid-resistant tuberculosis [‎TB]‎ in 42 patients attending a TB referral centre in the Islamic Republic of Iran. The patients were divided into 2 treatment groups: 26 received the 6-month standard HRZE treatment and 16 received a modified treatment of RZE for 6 months. There were no significant differences in age or sex of the groups. With the standard method of treatment, 21 [‎80.8%]‎ patients were cured, 4 [‎15.4%]‎ resulted in treatment failure, and 1 [‎3.8%]‎ died. In the modified treatment ...
  • Thumbnail

    The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance 

    World Health Organization (‎2016)‎

Show Statistical Information

View Item 
  • IRIS Home
  • 1. Headquarters
  • Publications
  • View Item
  • IRIS Home
  • 1. Headquarters
  • Publications
  • View Item

© WHO 2017

Quick Links

Sitemap

  • Home
  • Health topics
  • Data
  • Media centre
  • Publications
  • Countries
  • Programmes and projects
  • Governance
  • About WHO

Help and Services

  • Contacts
  • FAQs
  • Employment
  • Feedback
  • Privacy
  • E-mail scams

WHO Regional Offices

  • WHO African Region
  • WHO Region of the Americas
  • WHO South-East Asia Region
  • WHO European Region
  • WHO Eastern Mediterranean Region
  • WHO Western Pacific Region